Doyle Frank, Byrne David, Carney Robert M, Cuijpers Pim, Dima Alexandra L, Freedland Kenneth, Guerin Suzanne, Hevey David, Kathuria Bishember, Kelly Shane, McBride Stephen, Wallace Emma, Boland Fiona
Division of Population Health Sciences, RCSI University of Medicine and Health Sciences, Ireland.
Department of Psychiatry, Washington University School of Medicine, Missouri, USA.
BJPsych Open. 2023 Aug 11;9(5):e157. doi: 10.1192/bjo.2023.544.
Modern psychometric methods make it possible to eliminate nonperforming items and reduce measurement error. Application of these methods to existing outcome measures can reduce variability in scores, and may increase treatment effect sizes in depression treatment trials.
We aim to determine whether using confirmatory factor analysis techniques can provide better estimates of the true effects of treatments, by conducting secondary analyses of individual patient data from randomised trials of antidepressant therapies.
We will access individual patient data from antidepressant treatment trials through Clinicalstudydatarequest.com and Vivli.org, specifically targeting studies that used the Hamilton Rating Scale for Depression (HRSD) as the outcome measure. Exploratory and confirmatory factor analytic approaches will be used to determine pre-treatment (baseline) and post-treatment models of depression, in terms of the number of factors and weighted scores of each item. Differences in the derived factor scores between baseline and outcome measurements will yield an effect size for factor-informed depression change. The difference between the factor-informed effect size and each original trial effect size, calculated with total HRSD-17 scores, will be determined, and the differences modelled with meta-analytic approaches. Risk differences for proportions of patients who achieved remission will also be evaluated. Furthermore, measurement invariance methods will be used to assess potential gender differences.
Our approach will determine whether adopting advanced psychometric analyses can improve precision and better estimate effect sizes in antidepressant treatment trials. The proposed methods could have implications for future trials and other types of studies that use patient-reported outcome measures.
现代心理测量方法能够剔除无效项目并减少测量误差。将这些方法应用于现有的疗效指标可降低分数的变异性,并可能增大抑郁症治疗试验中的治疗效应量。
我们旨在通过对来自抗抑郁治疗随机试验的个体患者数据进行二次分析,确定使用验证性因素分析技术是否能更好地估计治疗的真实效果。
我们将通过Clinicalstudydatarequest.com和Vivli.org获取抗抑郁治疗试验的个体患者数据,特别针对那些使用汉密尔顿抑郁评定量表(HRSD)作为疗效指标的研究。探索性和验证性因素分析方法将用于确定抑郁症的治疗前(基线)和治疗后模型,包括因素数量和每个项目的加权分数。基线测量和结局测量之间导出的因素分数差异将产生因素告知的抑郁症变化的效应量。将确定因素告知的效应量与使用HRSD - 17总分计算的每个原始试验效应量之间的差异,并用荟萃分析方法对这些差异进行建模。还将评估达到缓解的患者比例的风险差异。此外,测量不变性方法将用于评估潜在的性别差异。
我们的方法将确定采用先进的心理测量分析是否能提高抗抑郁治疗试验的精度并更好地估计效应量。所提出的方法可能会对未来试验以及其他使用患者报告结局指标的研究类型产生影响。